A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs SHR 4640 (Primary)
  • Indications Gout; Hyperuricaemia
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 29 Mar 2017 Status changed from recruiting to completed.
    • 26 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016.
    • 22 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top